About Integumen
Integumen is a company based in Dublin (Ireland) founded in 2017. It operates as a B2B. Integumen has completed 3 acquisitions, including Cellulac, Modern Water and RinoCloud. Integumen operates in a competitive market with competitors including GSK, Avidity Biosciences, Castle Biosciences, Sutro Biopharma and Antheia, among others.
- Headquarter Dublin, Ireland
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$1.84 M (USD), Post-IPO
Dec 09, 2019
-
Investors
Not available
-
Employee Count
Not available
-
Investments & Acquisitions
Cellulac
& 2 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Integumen
Investments & Acquisitions by Integumen
Integumen has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Cellulac, Modern Water and RinoCloud.
Investment portfolio details for Integumen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Enterprise data collaboration and research organization platform is provided.
|
Locked | Locked | 2016 | Locked | |
|
Bioprocess technologies for biofuels and biochemicals are commercialized.
|
Locked | Locked | 2009 | Locked | |
|
Membrane-based technologies are developed for wastewater treatment processes.
|
Locked | Locked | 2006 | Locked |
Complete acquisition details for Integumen
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Integumen
Detailed financials for Integumen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Integumen Comparisons
Peer comparison for Integumen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Integumen
Integumen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Castle Biosciences, Sutro Biopharma and Antheia, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Adhesive patch biopsies for skin cancer detection are provided.
|
Detailed competitors of Integumen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Integumen
Complete news archive for Integumen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Integumen
Integumen was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Integumen is headquartered in Dublin, Ireland.
Integumen, established in 2017 and currently in Dissolved stage, focuses on providing healthcare solutions, advancing biotech innovations, skincare products, and wound dressing. Develops innovative technologies for skincare and wound dressing products. Adapting to market demands with innovation and client-focused strategies.
Integumen's top competitors include Sutro Biopharma, Synthego and Imbed Biosciences.
Integumen has made 3 acquisitions, including Cellulac, Modern Water, and RinoCloud.